GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 162 | 468 | -5,171 | -4,410 | -3,010 |
| Depreciation Amortization | 538 | 294 | 43 | 50 | 49 |
| Other Working Capital | 243 | 146 | 538 | 1,750 | 1,689 |
| Other Operating Activity | -1,061 | -1,046 | 3,603 | 1,837 | 777 |
| Operating Cash Flow | $-118 | $-138 | $-987 | $-773 | $-495 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -2 | N/A | N/A |
| Investing Cash Flow | $N/A | $N/A | $-2 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 35 | 35 | N/A | 615 | 408 |
| Debt Issued | N/A | N/A | 930 | N/A | N/A |
| Debt Repayment | -34 | -34 | N/A | N/A | N/A |
| Financing Cash Flow | $1 | $1 | $930 | $615 | $408 |
| Beginning Cash Position | 123 | 123 | 92 | 92 | 92 |
| End Cash Position | 11 | N/A | 123 | 61 | 5 |
| Net Cash Flow | $-112 | $-123 | $31 | $-31 | $-87 |
| Free Cash Flow | |||||
| Operating Cash Flow | -118 | -138 | -987 | -773 | -495 |
| Capital Expenditure | N/A | N/A | -2 | N/A | N/A |
| Free Cash Flow | -118 | -138 | -989 | -773 | -495 |